Masters Speciality Pharma is pleased to announce a partnership agreement with ApoPharma for the exclusive distribution of Ferriprox® (deferiprone) into India, Pakistan and Sri-Lanka. Masters has over 29 years’ experience in the ethical and compliant supply of drugs into countries where an unmet need for the medication exists. Our regulatory authorisation, licenses and capabilities will ensure that through Masters, access is created in the specified countries for those patients’ requiring Ferriprox®. Ferriprox® is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.
Lawrence Isaacs, Associate Director, Marketing, Sales and Business Development, ApoPharma said:
Collaborating with Masters in a drive to distribute the product is essential for us to maximise our efforts to ensure supply across these territories where unmet need exists.
“If it’s difficult for patients to access suitable treatment it compromises their health in a way that can have serious consequences for their future wellbeing” said Heather Gamble, Business Marketing Director, Masters Speciality Pharma.